药物诱导的胰岛素自身免疫综合征:FAERS数据库和网络药理学分析
Sa Xiao1, Long Lin2, Xiao-Hong Chen3
1Department of Pharmacy, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan 528200, Guangdong, China.
Endocrine, metabolic & immune disorders drug targets
|August 24, 2025
概括
这项研究发现了17种新药与胰岛素自身免疫综合征 (IAS) 的相关性,这种罕见的疾病会导致低血糖症. 卡普托普利,蒂亚马和克洛皮多格勒与潜在的PI3K-Akt通路相关.
科学领域:
- 药物监督管理
- 免疫学
- 药物安全
背景情况:
- 胰岛素自身免疫综合征 (IAS) 是一种罕见的药物不良反应,导致胰岛素自身抗体导致低血糖.
- 现有的文献缺乏有关IAS相关药物的系统药监数据.
研究的目的:
- 通过药监数据识别与IAS相关的药物.
- 探索药物诱导的潜在分子机制.
主要方法:
- 对IAS报告进行分析的FDA不良事件报告系统 (FAERS) 数据 (2004-2024年).
- 使用不成比例分析,药物基因相互作用网络和途径丰富分析.
主要成果:
- 确定了与IAS相关的17种药物,其中16种是新发现.
- 卡普托普里尔显示出最强的相关性,其次是蒂亚马和克洛皮多格勒.
- 观察到PI3K-Akt信号传递,胰岛素抵抗和AMPK通路的丰富.
结论:
- 发现了与IAS相关的新药,包括卡普托普利,蒂亚马和克洛皮多格勒.
- PI3K-Akt路径可能与IAS发展有关.
- 对于高危患者,建议加强低血糖监测.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
257
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
257
Insulin: The Receptor and Signaling Pathways
1.5K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.5K
Insulin: Biosynthesis, Chemistry, and Preparation
523
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
523
Diabetes Mellitus: Overview and Type I Subtype
3.2K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.2K
Insulin Formulations: Types and Delivery
270
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
270
Hypoglycemia and Glucagon
334
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
334


